Compare Sea Limited (SE) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sea Limited vs TransMedics Group Inc — how do they compare? Sea Limited trades at $96 (market cap $56.89B), while TransMedics Group Inc trades at $80.69 (market cap $2.74B). The key difference: Sea Limited is far larger — about 20.8× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 5,359,457). Which is the better fit depends on your goals — on Pluang, investors hold Sea Limited for 102 Days and TransMedics Group Inc for 24 Days on average.
| SE | TMDX | |
|---|---|---|
Market Cap | $56.89B | $2.74B |
Volume | 5,359,457 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $188.00 | $150.42 |
52-Week Low | $78.16 | $61.99 |
Typical Hold Time | 102 Days | 24 Days |
Enterprise Value | $51.92B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sea Limited (SE) trades at $94.66, down 1.94% with bearish technical signals despite strong fundamentals. The company shows robust revenue growth from $16.8B in 2024 to $22.9B in 2025, with net income reaching $1.58B. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss. Analyst consensus remains strongly bullish with a $153.67 price target, representing 62% upside potential from current levels.
The stock presents a compelling growth opportunity with improving profitability and strong cash flow generation, though technical weakness and insider selling create near-term headwinds. Key risks include execution challenges in e-commerce profitability and competitive pressures in Southeast Asian markets. The disconnect between strong fundamentals and bearish technicals suggests potential for recovery if earnings momentum continues.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
